公开(公告)号：US20060178388A1

公开(公告)日：2006-08-10

申请号：US11344881

申请日：2006-02-01

申请人： Stephen Wrobleski ,  Shuqun Lin ,  Katerina Leftheris ,  Liqi He ,  Steven Seitz ,  Tai-An Lin ,  Wayne Vaccaro

发明人： Stephen Wrobleski ,  Shuqun Lin ,  Katerina Leftheris ,  Liqi He ,  Steven Seitz ,  Tai-An Lin ,  Wayne Vaccaro

IPC分类号： A61K31/506 ,  C07D239/32 ,  C07D403/02

CPC分类号： C07D417/14 ,  C07D401/04 ,  C07D413/04 ,  C07D417/04

摘要： Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is —CR1; R1 is hydrogen or —CN; and N, G, Z, R2, R3, R4, R5, and R6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.

摘要翻译： 具有式（I）的化合物及其药学上可接受的盐及其溶剂化物可用作激酶抑制剂，其中：X 1，X 2和X 2中的两个， SUB> 3 是N，X 1，X 2和X 3中的剩余的一个是-CR _{1 ; R 1是氢或-CN; 和N，G，Z，R 2，R 3，R 4，R 5和R 5， SUB> 6 在说明书中描述。 还公开了含有式（I）化合物的药物组合物，以及治疗与p38激酶活性相关的病症和/或与LIM激酶活性相关的病症的方法。}

公开(公告)号：US07923556B2

公开(公告)日：2011-04-12

申请号：US12570010

申请日：2009-09-30

申请人： Stephen T. Wrobleski ,  Shuqun Lin ,  Katerina Leftheris ,  Liqi He ,  Steven P. Seitz ,  Tai-An Lin ,  Wayne Vaccaro

发明人： Stephen T. Wrobleski ,  Shuqun Lin ,  Katerina Leftheris ,  Liqi He ,  Steven P. Seitz ,  Tai-An Lin ,  Wayne Vaccaro

IPC分类号： C07D403/04 ,  C07D403/14 ,  A61K31/506 ,  A61P19/02 ,  A61K31/53 ,  C07D401/04 ,  C07D401/14

CPC分类号： C07D417/14 ,  C07D401/04 ,  C07D413/04 ,  C07D417/04

摘要： Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is —CR1; R1 is hydrogen or —CN; and N, G, Z, R2, R3, R4, R5, and R6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.

摘要翻译： 具有式（I）的化合物及其药学上可接受的盐及其溶剂合物可用作激酶抑制剂，其中：X1，X2和X3中的两个为N，X1，X2和X3中的其余一个为-CR1 ; R1是氢或-CN; 并且在说明书中描述了N，G，Z，R2，R3，R4，R5和R6。 还公开了含有式（I）化合物的药物组合物，以及治疗与p38激酶活性相关的病症和/或与LIM激酶活性相关的病症的方法。

公开(公告)号：US20100029649A1

公开(公告)日：2010-02-04

申请号：US12570010

申请日：2009-09-30

申请人： Stephen T. Wrobleski ,  Shuqun Lin ,  Katerina Leftheris ,  Liqi He ,  Steven P. Seitz ,  Tai-An Lin ,  Wayne Vaccaro

发明人： Stephen T. Wrobleski ,  Shuqun Lin ,  Katerina Leftheris ,  Liqi He ,  Steven P. Seitz ,  Tai-An Lin ,  Wayne Vaccaro

IPC分类号： A61K31/5377 ,  C07D417/04 ,  A61K31/506 ,  A61P29/00 ,  A61P35/00 ,  C07D417/14 ,  A61K31/497 ,  A61K31/496 ,  C07D413/14

CPC分类号： C07D417/14 ,  C07D401/04 ,  C07D413/04 ,  C07D417/04

摘要： Compounds having the formula (I), and pharmaceutically acceptable salts, and solvates thereof, are useful as kinase inhibitors, wherein: two of X1, X2, and X3 are N, and the remaining one of X1, X2, and X3 is —CR1; R1 is hydrogen or —CN; and N, G, Z, R2, R3, R4, R5, and R6 are described in the specification. Also disclosed are pharmaceutical compositions containing compounds of formula (I), and methods of treating conditions associated with the activity of p38 kinase and/or conditions associated with the activity of LIM kinase.

摘要翻译： 具有式（I）的化合物及其药学上可接受的盐及其溶剂合物可用作激酶抑制剂，其中：X1，X2和X3中的两个为N，X1，X2和X3中的其余一个为-CR1 ; R1是氢或-CN; 并且在说明书中描述了N，G，Z，R2，R3，R4，R5和R6。 还公开了含有式（I）化合物的药物组合物，以及治疗与p38激酶活性相关的病症和/或与LIM激酶活性相关的病症的方法。

公开(公告)号：US08188090B2

公开(公告)日：2012-05-29

申请号：US12614497

申请日：2009-11-09

申请人： Fariborz Firooznia ,  Tai-An Lin ,  Sung-Sau So ,  Baoxia Wang ,  HongYing Yun

发明人： Fariborz Firooznia ,  Tai-An Lin ,  Sung-Sau So ,  Baoxia Wang ,  HongYing Yun

IPC分类号： A61K31/445 ,  A61K31/4965 ,  A01N43/40 ,  C07D241/04 ,  C07D295/00 ,  C07D205/00

CPC分类号： C07D295/192 ,  C07D213/74 ,  C07D239/42 ,  C07D295/18 ,  C07D401/12 ,  C07D487/10

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q and R1-R3 are defined in the detailed description and claims. The invention is also concerned with the compounds of formula Z: and pharmaceutically acceptable salts and esters thereof, wherein R1-R3 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I and Z as well as pharmaceutical compositions containing such compounds. The compounds of formula I and Z are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中X，Q和R 1 -R 3在详细描述和权利要求书中定义。 本发明还涉及式Z化合物及其药学上可接受的盐和酯，其中R1-R3在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I和Z化合物的方法以及含有这些化合物的药物组合物。 式I和Z的化合物是CRTH2受体的拮抗剂或部分激动剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US07517482B2

公开(公告)日：2009-04-14

申请号：US11269611

申请日：2005-11-09

申请人： Tung-Liang Huang ,  Ting-Huei Wang ,  Chun-Wei Lai ,  Tai-An Lin

发明人： Tung-Liang Huang ,  Ting-Huei Wang ,  Chun-Wei Lai ,  Tai-An Lin

IPC分类号： B29C65/00 ,  B01D39/00 ,  B01D39/14

CPC分类号： B01D67/0011 ,  B01D67/0016 ,  B01D69/02 ,  B01D71/16 ,  B01D71/68 ,  B01D2323/12 ,  B01D2325/022

摘要： A method for preparing polymeric membranes is disclosed, which has the following steps: (a) forming a casting solution by dissolving cellulose triacetate (CTA) and polyether-sulfone (PES) in a solvent mixture containing n-methyl pyrroridone (NMP) and hydrogen chloride (HCl); (b) forming a membrane from said casting solution; and (c) recovering said membrane. The method of present invention provides an asymmetrical, microporous, polymeric membrane with a high recovery rate of nucleic acids and desirable bulk and surface properties. Also, the membrane so-produced is useful to the application of material separations by filtration and the like, especially the condensation of nucleic acids from a crude sample by filtration.

摘要翻译： 公开了一种制备聚合物膜的方法，其具有以下步骤：（a）通过将三乙酸纤维素（CTA）和聚醚砜（PES）溶解在含有正甲基吡咯烷酮（NMP）和氢气的溶剂混合物中形成浇铸溶液 氯化物（HCl）; （b）从所述浇铸溶液形成膜; 和（c）回收所述膜。 本发明的方法提供了具有高回收率的核酸和所需的体积和表面性质的不对称的微孔聚合物膜。 此外，如此制备的膜可用于通过过滤等应用材料分离，特别是通过过滤从粗样品中冷凝核酸。

公开(公告)号：US20100137250A1

公开(公告)日：2010-06-03

申请号：US12614478

申请日：2009-11-09

申请人： Fariborz Firooznia ,  Paul Gillespie ,  Tai-An Lin ,  Eric Mertz ,  Achyutharao Sidduri ,  Sung-Sau So ,  Jenny Tan ,  Kshitij Chhabilbhai Thakkar

发明人： Fariborz Firooznia ,  Paul Gillespie ,  Tai-An Lin ,  Eric Mertz ,  Achyutharao Sidduri ,  Sung-Sau So ,  Jenny Tan ,  Kshitij Chhabilbhai Thakkar

IPC分类号： A61K31/69 ,  C07C63/33 ,  A61K31/18 ,  C07D295/00 ,  A61K31/535 ,  C07C69/76 ,  C07D239/00 ,  C07D239/42

CPC分类号： C07D295/26 ,  C07C57/58 ,  C07C59/68 ,  C07C69/76 ,  C07C255/57 ,  C07C311/16 ,  C07C311/29 ,  C07C317/44 ,  C07C317/46 ,  C07C323/62 ,  C07D231/12 ,  C07D239/26 ,  C07D257/04 ,  C07D317/70

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein X, Q, and R1-R6 are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists or partial agonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中X，Q和R 1 -R 6在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂或部分激动剂，可用于治疗与该受体相关的疾病和病症，例如哮喘。

公开(公告)号：US20120309796A1

公开(公告)日：2012-12-06

申请号：US13469177

申请日：2012-05-11

申请人： Fariborz Firooznia ,  Paul Gillespie ,  Tai-An Lin ,  Sung-Sau So

发明人： Fariborz Firooznia ,  Paul Gillespie ,  Tai-An Lin ,  Sung-Sau So

IPC分类号： A61K31/196 ,  C07D213/34 ,  A61K31/4418 ,  A61P11/06 ,  C07C311/28 ,  C07C323/67 ,  C07C317/14 ,  C07D213/71 ,  C07C311/20 ,  A61P11/00

CPC分类号： C07D213/34 ,  C07C311/20 ,  C07C311/29 ,  C07C317/14 ,  C07C323/67 ,  C07C2602/12 ,  C07D213/71

摘要： Provided herein are compounds of the formula (I): as well as pharmaceutically acceptable salts thereof, wherein the substituents are as those disclosed in the specification. These compounds, and the pharmaceutical compositions containing them, are useful for the treatment of inflammatory diseases and disorders such as, for example, asthma and COPD.

摘要翻译： 本文提供式（I）的化合物及其药学上可接受的盐，其中取代基如说明书中公开的那些。 这些化合物和含有它们的药物组合物可用于治疗炎性疾病和病症，例如哮喘和COPD。

公开(公告)号：US20120095053A1

公开(公告)日：2012-04-19

申请号：US13324650

申请日：2011-12-13

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

IPC分类号： A61K31/4439 ,  C07D401/12 ,  A61P11/06 ,  C07D405/14

CPC分类号： C07D231/56 ,  C07D401/12

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中Q，R 1 -R 3和n在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US20100016369A1

公开(公告)日：2010-01-21

申请号：US12497807

申请日：2009-07-06

申请人： Li Chen ,  Fariboz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

发明人： Li Chen ,  Fariboz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun ,  Zhenshan Zhang

IPC分类号： A61K31/4439 ,  C07D231/54 ,  A61K31/416 ,  C07D401/02

CPC分类号： C07D231/56 ,  C07D401/12 ,  C07D413/12

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, W, X, R1-R5 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中Q，W，X，R 1 -R 5和n在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。

公开(公告)号：US20100016368A1

公开(公告)日：2010-01-21

申请号：US12497786

申请日：2009-07-06

申请人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

发明人： Li Chen ,  Fariborz Firooznia ,  Paul Gillespie ,  Yun He ,  Tai-An Lin ,  Sung-Sau So ,  HongYing Yun

IPC分类号： A61K31/416 ,  C07D231/56 ,  C07D401/12 ,  A61K31/4439

CPC分类号： C07D231/56 ,  C07D401/12

摘要： The invention is concerned with the compounds of formula I: and pharmaceutically acceptable salts and esters thereof, wherein Q, R1-R3 and n are defined in the detailed description and claims. In addition, the present invention relates to methods of manufacturing and using the compounds of formula I as well as pharmaceutical compositions containing such compounds. The compounds of formula I are antagonists at the CRTH2 receptor and may be useful in treating diseases and disorders associated with that receptor such as asthma.

摘要翻译： 本发明涉及式I化合物及其药学上可接受的盐和酯，其中Q，R 1 -R 3和n在详细描述和权利要求书中定义。 此外，本发明涉及制备和使用式I化合物的方法以及含有这些化合物的药物组合物。 式I化合物是CRTH2受体的拮抗剂，可用于治疗与该受体相关的疾病和病症如哮喘。